EP0341774A1 — Pharmaceutical solutions of triamterene
Assigned to Multilan AG · Expires 1989-11-15 · 37y expired
What this patent protects
A pharmaceutically acceptable solution of triamterene and solutions of triamterene and other therapeutically active drugs, in particular hydrochlorothiazide. Triamterene is solubilized in a combination of a glycol and lactic acid present in an amount sufficient to maintain the tr…
USPTO Abstract
A pharmaceutically acceptable solution of triamterene and solutions of triamterene and other therapeutically active drugs, in particular hydrochlorothiazide. Triamterene is solubilized in a combination of a glycol and lactic acid present in an amount sufficient to maintain the triamterene in solution. A pharmaceutically acceptable diluent, such as glycerin, is preferably also present.
Drugs covered by this patent
- Microzide (hydrochlorothiazide) · Generic (originally Merck)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.